NCT04798677View on ClinicalTrials.gov

Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

NACompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

June 10, 2021

Study Completion Date

September 24, 2021

Conditions
ImmunityVaccine ReactionInfluenzaCovid19Cytokine StormImmunologic Deficiency Syndromes
Interventions
DIETARY_SUPPLEMENT

ABBC1 Immunoessential

Powder for dissolution in water, based on a yeast beta-glucan complex and a consortium of Saccharomyces cerevisiae rich in selenium and zinc + excipents. Lemon flavor

DIETARY_SUPPLEMENT

Placebo

Powder for dissolution in water, excipents. Lemon flavor

Trial Locations (1)

08042

Hospital Mare de Déu de la Mercè - Germanes Hospitalàries, Barcelona

Sponsors

Lead Sponsor

AB Biotek
All Listed Sponsors
lead

AB Biotek

INDUSTRY

NCT04798677 - Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine | Biotech Hunter | Biotech Hunter